Please assess the completion status of the following clinical trial:

Trial Title: Cycloserine in the Treatment of Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe obstructive or central sleep apnea (Apnea Hypopnea Index \> 30/hr).~* Minimum Oxygen saturation during respiratory events \>70% throughout sleep during the clinical sleep study.~Exclusion Criteria:~* Contraindication to the use of cycloserine, namely history of allergy to cycloserine, seizures, depression, severe anxiety or psychosis, excessive use of alcohol or renal failure.~* Past or current history of tuberculosis~* Hypercapnia \> 55 millimeters of mercury during the diagnostic clinical sleep study.~* Neuromuscular disease.~* Obesity-hypoventilation syndrome.~* Pregnancy.~* Significant co-morbidities: Dialysis-dependant renal failure, severe asthma or chronic lung disease, congestive heart failure, previous stroke.~* Recent (within 3 months) myocardial infarction or Active coronary ischemia event.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cycloserine (Type: ACTIVE_COMPARATOR): Cycloserine, 250 mg capsules by mouth, one hour prior to initiation of sleep study, single dose
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, sugar capsule by mouth, one hour prior to initiation of sleep study, single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).